Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.

Journal of the National Cancer Institute - 1 Oct 2008

Eisen Andrea, Lubinski Jan, Gronwald Jacek, Moller Pal, Lynch Henry T, Klijn Jan, Kim-Sing Charmaine, Neuhausen Susan L, Gilbert Lucy, Ghadirian Parviz, Manoukian Siranoush, Rennert Gad, Friedman Eitan, Isaacs Claudine, Rosen Eliot, Rosen Barry, Daly Mary, Sun Ping, Narod Steven A

Abstract excerpt

BACKGROUND: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Confounding Factors, Epidemiologic
Share to Estrogen Replacement Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogens

Share to Genes, BRCA1

Share to Postmenopause

Share to Progestins

Share to Sample Size

Share to Surveys and Questionnaires

Source

Open in PubMed Open full text

Identifiers

PMID: 18812548
DOI: 10.1093/jnci/djn313
PMCID: PMC2556701

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.PMID 18812548Read ↗

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.Semantic proximity Read ↗

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.Semantic proximity Read ↗

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.Semantic proximity Read ↗

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Semantic proximity Read ↗

BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study.Semantic proximity Read ↗

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.